On the contrary, patients with low levels of CD161 expression associated with shorter OS in ACC, Breast invasive carcinoma (BRCA), BLCA, CESC, Cholangiocarcinoma (CHOL), KIRC, HNSC, KIRP, LUAD, LIHC, Mesothelioma (MESO), PAAD, OV, READ, Pheochromocytoma and Paraganglioma (PCPG), PRAD, Sarcoma (SARC), Uterine Corpus Endometrial Carcinoma (UCEC), SKCM, Thyroid carcinoma (THCA, Figures 2A, B, S1). This evidence concerns the gene KLRB1 and sarcoma.